期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome 被引量:1
1
作者 Feng Lin Thomas E Ichim +3 位作者 Sandeep Pingle Lawrence D Jones Santosh Kesari shashaanka ashili 《World Journal of Stem Cells》 SCIE CAS 2020年第10期1067-1079,共13页
Coronavirus disease 2019(COVID-19),a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV2),is growing at an exponential rate worldwide.Manifestations of this disease are heterogeneo... Coronavirus disease 2019(COVID-19),a pandemic disease caused by the severe acute respiratory syndrome coronavirus 2(SARS-CoV2),is growing at an exponential rate worldwide.Manifestations of this disease are heterogeneous;however,advanced cases often exhibit various acute respiratory distress syndrome-like symptoms,systemic inflammatory reactions,coagulopathy,and organ involvements.A common theme in advanced COVID-19 is unrestrained immune activation,classically referred to as a“cytokine storm”,as well as deficiencies in immune regulatory mechanisms such as T regulatory cells.While mesenchymal stem cells(MSCs)themselves are objects of cytokine regulation,they can secrete cytokines to modulate immune cells by inducing antiinflammatory regulatory Treg cells,macrophages and neutrophils;and by reducing the activation of T and B cells,dendritic and nature killer cells.Consequently,they have therapeutic potential for treating severe cases of COVID-19.Here we discuss the unique ability of MSCs,to act as a“living antiinflammatory”,which can“rebalance”the cytokine/immune responses to restore equilibrium.We also discuss current MSC trials and present different concepts for optimization of MSC therapy in patients with COVID-19 acute respiratory distress syndrome. 展开更多
关键词 Mesenchymal stem cells SARS-CoV-2 COVID-19 Cytokine storm Acute respiratory distress syndrome IMMUNOMODULATION
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部